RESEARCH
Our research focuses on advancing women’s reproductive health through nanomedicine and nano theranostics, targeting conditions like ectopic pregnancy, endometriosis, choriocarcinoma, and placenta-related diseases. By developing innovative nanomaterials for imaging and therapy, including photo-theranostic agents, our lab aims to improve early diagnosis and enable precise, effective treatments.
Nanotheranostics for Precision Imaging and Photo-Induced Hyperthermia
Our lab develops theranostic nanoscale agents that use photo-induced hyperthermia for precise, non-invasive treatment of targeted tissues, including applications in ectopic pregnancy. Using near-infrared (NIR) dye-loaded nanoparticles, we achieve real-time visualization through fluorescence and photoacoustic imaging. Upon NIR light activation, these nanoparticles generate localized heat to disrupt specific tissues without affecting surrounding areas, allowing for both accurate diagnosis and immediate treatment. This approach opens new possibilities for managing complex conditions with high precision and minimal invasiveness.
Nano-Theranostic Modality for Visualization of the Placenta and Photo-Hyperthermia for Potential Management of Ectopic Pregnancy. Moses et al. Small 2022
Graphics by: Parinaz Ghanbari
Enhanced Drug Delivery Systems for Improved Management of Ectopic Pregnancy
Our work also focuses on improving drug delivery systems for the management of ectopic pregnancy, particularly through the use of methotrexate (MTX), the current first-line treatment. We develop innovative nanocarriers that enhance the targeting and release of MTX specifically at the implantation site, addressing the significant therapeutic failures associated with conventional MTX treatment. By ensuring more efficient drug accumulation and controlled release, our approach aims to increase treatment efficacy while minimizing side effects. This strategy has the potential to significantly improve outcomes in ectopic pregnancy management and reduce associated risks.
Glutathione-Responsive Methotrexate Polymersomes for Potential Management of Ectopic Pregnancy. Mamnoon et al. Small 2023
Graphics by: Parinaz Ghanbari
Targeted Drug Delivery Systems for Enhanced Treatment of Choriocarcinoma
Our research aims to develop targeted drug delivery systems for gestational choriocarcinoma (CC), a rare and aggressive cancer affecting women’s reproductive health. We aim to improve treatment efficacy by enhancing the delivery of methotrexate (MTX) directly to CC tumors. By utilizing innovative nanocarrier platforms that specifically target cancer cells, we increase drug accumulation at the tumor site while minimizing side effects. This targeted approach has the potential to significantly enhance treatment outcomes for women diagnosed with choriocarcinoma.
ENT-1-Targeted Polymersomes to Enhance the Efficacy of Methotrexate in Choriocarcinoma Treatment. Mamnoon & Mesquita et al. Small Science 2025.
Graphics by Parinaz Ghanabri
Financial Support
National Institute of Health:
NIH/NICHD R01 Award. Nanoparticle-mediated placental imaging and magnetic hyperthermia for management of ectopic pregnancy
NIH/NICHD R01 AWARD, Grant No. R01 HD101450-01A1: Development of Magnetic Hyperthermia for the Systemic Treatment of Endometriosis
NIH/NCATS R03 Award. Grant No. R03TR004020-01: Nanocarriers for Placenta-Specific Delivery of Imaging and Therapeutic Agents
NIH/NCATS, KL2 Award, Grant No. KL2 TR002370: Multifunctional Theranostic Nanoplatform for Image-Guided Surgery and Phototherapy
M.J. Murdock Charitable Trust, Center for Innovative Drug Delivery and Imaging (CIDDI): cGMP Manufacturing of Nanomedicines for preclinical and clinical trials
Circle of Giving, OHSU Foundation. Novel targeted nanoparticles to improve detection and visualization of abnormal placentation
OSU College of Pharmacy